Search PubMed⌕ Search

Biomedical subjects

M C Beinfeld

Publications and source records attributed to M C Beinfeld.

At least 127 records · Page 7Linked to original sources
PubMed1981

Identification, characterization and distribution of motilin immunoreactivity in the rat central nervous system.

Motilin-immunoreactivity was evaluated in rat brain using 15 different antisera and by combining gel filtration, high pressure gel filtration and reverse phase high pressure liquid chromatography with radioimmunoassay. Gel filtration chromatography demonstrated a high molecular weight and low molecular weight form of immunoreactive motilin. The high molecular weight form predominated in brain while the low molecular weight peptide was the predominant form of duodenum. The low molecular weight immunoreactive motilin was indistinguishable from synthetic porcine motilin by gel filtration and high molecular weight gel filtration. Low molecular weight rat motilin could, however, be distinguished from synthetic porcine motilin by high pressure liquid chromatography and certain antisera. Immunological results suggest that the slight structural difference may be in the N-terminal portion of the molecule. Immunoreactivity was measured in grossly and microdissected regions of the rat brain. The peptide had quite a unique distribution as highest concentrations are observed in the cerebellum. High concentrations were also observed in hypothalamic nuclei. Particularly high concentrations were noted in the organum vasculosum lamina terminalis. Lowest motilin concentrations in the rat brain were in the pons and the medulla. The distribution of motilin in rat brain suggests that it may have roles in regulating both neuroendocrine and neurological processes.

Animals↗
PubMed1981

Chemical heterogeneity in cerebellar Purkinje cells: existence and coexistence of glutamic acid decarboxylase-like and motilin-like immunoreactivities.

Purkinje neurons of the cerebellar cortex from a chemically and morphologically heterogeneous population containing some members that have gamma-aminobutyric acid (GABA), others that have immunoreactivity for motilin, and a small number that have both. The remaining 30-40% of all Purkinje cells have neither of these two neuroactive substances, leaving possibilities for other transmitter candidates. The evidence was compiled from double-staining immunocytochemical procedures performed on single sections of the cerebellum and brain stem in rat, mouse, and monkey. Two polyclonal antibodies were applied in succession, one directed against the midregion and COOH terminus of the 22-amino acid polypeptide motilin and the other against glutamic acid decarboxylase (glutamate decarboxylase; L-glutamate 1-carboxy-lyase, EC 4.1.1.15), the rate-limiting enzyme in the synthesis of the neurotransmitter GABA. The staining combinations employed the immunoperoxidase method, with different chromogens for distinguishing the motilin-like immunoreactivity from glutamic acid decarboxylase immunoreactivity by different colors, or the immunoperoxidase method for one antiserum and immunofluorescence for the other. The locations of both motilin and GABA cell types were mapped. The recognition of motilin in Purkinje cells calls for experimental definition of the role of this substance in the cerebellum and for reevaluation of the roles of Purkinje cells and of GABA in cerebellar function. The significant motilin representation in the flocculus, paraflocculus, and vermis suggests that it may be the Purkinje cell mediative chemical in the vestibular parts of the cerebellum. However, the presence of GABA as well in the same regions indicates that the chemical preference may be at least bimodal.

Animals↗
PubMed1980

Cholecystokinin octapeptide in the rat hypothalamo-neurohypophysial system.

Gastrin-cholecystokinin (CCK)-like immunoreactivity has been visualized by immunohistochemistry in the vasopressin-oxytocin neurosecretory system comprising the posterior lobe of the pituitary, the supraoptic and paraventricular nuclei of the hypothalamus. This CCK-like substance has not been chemically identified in the rat, but has been reported to be gastrin 17 in the swine pituitary. We report here that this CCK-like immunoreactive substance co-chromatographs with CCK8 sulphate on Sephadex G-50 and two HPLC chromatographic systems. No gastrin 17 was detected in rat pituitary or brain. We further report that about 60% of the CCK in posterior lobe originates in cell bodies in the paraventricular nucleus of the hypothalamus. The CCK content of posterior pituitary is dramatically decreased by physiological perturbations which stimulate vasopressin or oxytocin release. We propose that CCK may either be co-secreted with vasopressin and oxytocin to act on peripheral targets or may be involved in the regulation of vasopressin or oxytocin neurosecretion.

Animals↗
PubMed1975

Effect of F-actin upon the binding of ADP to myosin and its fragments.

The effect of F-actin upon the binding of ADP to rabbit skeletal muscle myosin, heavy meromyosin, and subfragment 1 was studied by equilibrium dialysis, ultracentrifuge transport, and light scattering techniques. Both myosin and H-meromyosin (HMM) bind a maximum of approximately 1.6 mol of ADP/mol of protein, while S-1 binds approximately 0.9 mol of ADP/mol of protein. The affinity for ADP of all three preparations was similar at a given ionic strength (approximately 10(6) M-1 at 0.05 M KCl) and decreased with increasing ionic strength. Under conditions similar to those used for the measurement of ADP binding, the binding sites of myosin, HMM, and subfragment 1 (S-1) are saturated with actin at molar ratios of 2, 2, and 1 mol of actin monomer/mol of protein, respectively, as determined by light scattering, ultracentrifuge transport, and in the case of myosin by ATPase measurements. F-actin was found to inhibit ADP binding, but even at an actin concentration at least twice that required for saturation of myosin, HMM, or S-1, significant ADP binding remained. This ADP binding was inhibited by 10(-4) M pyrophosphate. The observations are consistent with the formation of an actomyosin-ADP complex in which actin and ADP are bound to myosin at distinct but interacting sites.

Actins↗
PubMed1975

The binding of divalent cations to myosin.

Centrifuge transport, equilibrium dialysis, and electron paramagnetic resonance studies on the binding of Mn2+ to myosin revealed two sets of noninteracting binding sites which are characterized at low ionic strength (0.016 M KCl) by affinity constants of 10(6) M-1 (Class I) and 10(3) M-1 (Class II), respectively. At 0.6 M KCl concentration, the affinity of Mn2+ for both sets of sites is reduced. The maximum number of binding sites is 2 for the high affinity and 20 to 25 for the low affinity set. Other divalent metal ions displace Mn2+ from the high affinity sites in the following order of effectiveness: Ca greater than Mg = Zn = Co greater than Sr greater than Ni. The inhibitory effects of Mg2+ and Ca2+ upon the Mn2+ binding are competitive with inhibitor constants of 0.75 to 1 mM which is similar to that of the low affinity divalent metal ion binding sites. Exposure of myosin to 37 degrees partially inhibits Mn2+ binding to Class I parallel with inhibition of ATPase activity. The binding of Mn2+ to the high affinity binding sites is not significantly influenced by ADP or PPi, although Mn2+ increases the affinity of ADP binding to myosin at high ionic strength.

Animals↗
PubMedDate not supplied

Cerebral ventricular transport and uptake: importance for CCK-mediated satiety.

Brain cholecystokinin (CCK) peptides have been proposed to be involved in the control of feed intake. We have examined the importance of the cerebral ventricular system in CCK-mediated satiety in sheep. Continuous injection of 0.64 pmol/min CCK-8 into the lateral ventricles (LV) decreased feeding, whereas injection of neither 0.64 nor 2.55 pmol/min CCK-8 into the cisterna magna (CM) significantly affected feeding. Thus, it is likely that the rostral, but not caudal, ventricular compartments and/or adjacent brain areas are involved in CCK-8 mediated satiety. The rate of injection of carrier solution (synthetic cerebrospinal fluid [CSF]) was found to affect feed intake during a continuous 75 min injection: feed intakes were greater during injection of sCSF at 0.10 ml/min than during either 0.03 ml/min sCSF or no injection (sham). Injection of 0.64 pmol/min CCK-8 in either 0.03 or 0.10 ml/min decreased feeding. The increased feeding during 0.10 ml/min sCSF injection may have been due to dilution of endogenous CCK released into CSF during the meal. To determine the percent recovery from CSF of exogenous CCK-8, CSF samples from CM were collected during 3 hr continuous LV injections of CCK-8 and inulin (for measurement of bulk absorption). Only 20 to 40 percent of administered CCK-8 was recovered in CM CSF. The loss of CCK-8 was probably not due to degradation in the CSF by proteolytic enzymes, since CCK-8 concentrations did not decrease during in vitro incubation at 37 degrees C for up to 24 hr. We propose that CCK-8 is released during feeding into the ventricular system, and subsequently taken up from CSF by specialized ependymal cells for transport to sites of action.

Animals↗
PubMedDate not supplied

Chromatographic characterization of gastrin/cholecystokinin peptides in bovine and porcine pituitary.

Gastrin/CCK peptides in extracts from bovine and porcine pituitary have been characterized by Sephadex gel filtration, reverse phase liquid chromatography and a CCK radioimmunoassay (RIA) which detects both CCK and gastrin [4]. Porcine pituitary extracts contain a small amount of two peptides with chromatographic behavior similar to porcine antral gastrins. However, bovine pituitaries lack gastrin and contain instead substantial quantities of a peptide which co-elutes with CCK8 sulfate. We have previously shown that rat pituitary also contains CCK8 sulfate-like peptides but lacks gastrin [3]. It is clear from this work that species differences exist in the gastrin/CCK pituitary peptides. This points out the necessity of a careful chemical characterization of pituitary gastrin/CCK peptides in any species prior to physiological or pharmacological experimentation.

Animals↗
PubMedDate not supplied

Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum.

A population of neurons in the hippocampus and subiculum contains cholecystokinin (CCK). Following transection of the dorsal fornix, a major afferent pathway of the hippocampus and associated structures. CCK levels were reduced in the septum and hypothalamus. A microdissection analysis indicated that the loss of CCK occurred in nuclei receiving direct projections from the hippocampus and subiculum, suggesting that CCK-containing neurons in the hippocampus and subiculum project to extrahippocampal regions.

Afferent Pathways↗
PubMedDate not supplied

The postnatal development of VIP binding sites in rat forebrain and hindbrain.

The specific binding of 125I-labeled vasoactive intestinal peptide (VIP) to brain membranes from the forebrain and hindbrain regions of 2 to 37-day postnatal rats was measured. In both regions of the brain, VIP binding was low but detectable two days after birth and rose markedly between postnatal days 7 and 17. This increase in VIP binding with age correlates well with observed increases in VIP-stimulated adenylate cyclase activity and increases in VIP content as determined by radioimmunoassay. In hindbrain, the density of VIP binding sites was substantially higher than the forebrain at two days, while at 37 days, they were about equal, suggesting that the hindbrain regions may mature neurochemically prior to the forebrain. Total binding sites for forebrain and hindbrain were about equal at birth for both brain regions, while forebrain had a substantially greater number of sites at 37 days postnatal. The presence of VIP binding sites in both forebrain and hindbrain early in postnatal development suggests that VIP may play a role in development of the brain.

Animals↗
PubMedDate not supplied

Peptides in rat brain immunoreactive for the carboxyl terminal extension of cholecystokinin: distribution and chromatography.

Utilizing an antiserum raised against a peptide fragment identical to part of the carboxyl terminal extension of cholecystokinin (CCK) predicted by the sequence of CCK mRNA [7], an antiserum has been generated which does not detect CCK 39, CCK 33, CCK 8, CCK 4 or gastrin 171. This antiserum detects several peptides in rat brain, one similar in size to CCK 33 and another slightly larger than CCK 8. These peptides may represent carboxyl-terminally extended forms of CCK, though their chemical structure has not been determined. These peptides are present in all brain regions where CCK 8 can be detected. The abundance of these peptides, their localization in CCK terminal regions, and their enrichment in synaptosome preparations [1] imply that the tryptic cleavage and amidation reaction occur late in the processing of CCK (as has been observed for other biologically active peptides), and probably occur in the synaptic vesicle.

Amino Acid Sequence↗
PubMedDate not supplied

Synthesis and release of vasoactive intestinal polypeptide (VIP) by mouse neuroblastoma cells: modulation by cyclic nucleotides and ascorbic acid.

The mouse neuroblastoma cell line N18TG2 synthesizes and secretes a VIP-like immunoreactive material. The majority of this VIP-like material from both cell and media extracts elutes on HPLC in the same position as porcine or rat VIP. Several additional peaks which appear in the media extracts may represent variant forms or degradation products of VIP. The synthesis and release of VIP was significantly enhanced by agents which elevate cAMP levels directly (dbcAMP and forskolin) or through a receptor mediated process (secretin). These agents are also known to promote differentiation of these cells. The synthesis and release of VIP was also enhanced by ascorbate (thought to be a co-factor for the enzyme which amidates the carboxyl-terminal of VIP) [11]. In the presence of forskolin, ascorbate had a synergistic effect on the release of VIP, suggesting that forskolin and ascorbate are elevating VIP levels by different mechanisms; forskolin through a possible effect on VIP mRNA synthesis or translation, and ascorbate by increasing the rate of VIP processing. These results suggest that VIP synthesis and release is controlled by more than one process, whose rate can be altered with pharmacological agents.

Animals↗
PubMedDate not supplied

Brain motilin-like peptides are localized within the cell nucleus.

The subcellular localization of motilin-like immunoreactive (MLIP) peptides in comparison to vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine amide-27-like peptide (PLP) was investigated in rat brain applying different subcellular fractionation techniques. Unlike VIP or PLP, motilin-like peptides were not located in synaptosomes, but in the cell nucleus. This is the first report of a non-vesicular localization of this neuropeptide and is suggestive of a possible non-neurotransmitter role of MLIP. Previous developmental studies point to a possible role for motilin-like peptides as trophic or developmental factors. These results open the possibility that brain motilin-like peptides may operate by binding to chromatin and regulating gene expression.

Animals↗
PubMedDate not supplied

Calcium-dependent pro-cholecystokinin V-9-M immunoreactive peptide release from rat brain slices and CCK-secreting rat medullary thyroid carcinoma cells in culture.

The release of peptides immunoreactive for a synthetic peptide (V-9-M) contained in the amino-terminal of pro-CCK was examined. The potassium-evoked release of V-9-M immunoreactive peptides from rat cerebral cortical slices in vitro was calcium dependent. Cholecystokinin-secreting rat medullary thyroid carcinoma cells also secreted significant quantities of these peptides. Sephadex column chromatography of the release media from slices and cells showed two V-9-M immunoreactive peptides, one larger and one smaller than V-9-M itself. Previous behavioral studies have suggested that V-9-M has a distinct neuropharmacological profile. These results demonstrate that V-9-M-like peptides are released along with CCK-8 and are consistent with the hypothesis that V-9-M-like peptides may be neurotransmitters or neuromodulators or may be involved in the sorting or transport of CCK-8.

Amino Acid Sequence↗
PubMedDate not supplied

Regulation of cholecystokinin secretion from a rat medullary thyroid carcinoma cell line: role of calcium, cyclic nucleotides, glucocorticoids, neurotensin, and calcitonin gene-related peptide.

CCK-secreting WE rat medullary thyroid carcinoma cell line resembles other calcitonin-producing (C-cell) lines in that calcium, cAMP, or agents which raise cAMP, dexamethasone, and beta-adrenergic agents all stimulate peptide secretion. Unlike other C-cell lines, the WE cells respond similarly to IBMX (3-isobutyl-1-methyl-xanthine, a phosphodiesterase inhibitor) in the presence and absence of forskolin, implying that these cells secrete substances that raise cAMP levels, whose effect is accentuated by IBMX. Both CGRP and neurotensin, peptides that may be secreted by these cells, caused a small, but significant, increase in CCK secretion. It is possible that these or other secreted substances that activate adenylate cyclase are responsible for the cell's high rate of CCK secretion. Their high rate of CCK synthesis and their regulated secretion suggest that these cells will be a good model for studies of CCK expression, biosynthesis, and processing.

Animals↗